SEC Tracker
Get the app

Myriad Genetics MYGN

Myriad Genetics Q1 FY26: revenue $200.4M, up 2%; diluted EPS −$0.36

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Myriad Genetics reported for Q1 FY26, the quarter ended Mar 31, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$200.4M+2% from $195.9M in Q1 FY2510-Q income statement, on EDGAR
  2. Net income−$34.1MAgainst −$100K in Q1 FY2510-Q income statement, on EDGAR
  3. Diluted EPS−$0.36Against $0.00 in Q1 FY2510-Q income statement, on EDGAR
  4. Cash and cash equivalents$124.4M+36% from $91.8M in Q1 FY2510-Q balance sheet, on EDGAR
  5. Cash from operations−$15.7MAgainst −$16.3M in Q1 FY2510-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Myriad Genetics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2835 and related industry codes: the same peer list as the financial tables.

  1. Kura Oncology KURA public float $496M, Jun 30, 2025
  2. KalVista Pharmaceuticals KALV public float $499M, Jun 30, 2025
  3. Arbutus Biopharma ABUS public float $472M, Jun 30, 2025
  4. Arvinas ARVN public float $469M, Jun 30, 2025
  5. aTYR PHARMA ATYR public float $464M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.